| Gene symbol | TERT | Synonyms | CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5p15.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | telomerase reverse transcriptase | ||||
| GTO ID | GTC3975 |
| Trial ID | NCT04391049 |
| Disease | Squamous Cell Carcinoma |
| Altered gene | E1A|E1B|TERT |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | Telomelysin|OBP-301 |
| Co-treatment | carboplatin|paclitaxel|radiation |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery |
| Year | 2021 |
| Country | United States |
| Company sponsor | NRG Oncology |
| Other ID(s) | NRG-GI007|NCI-2020-02320|NRG-GI007|NRG-GI007|U10CA180868 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort 1 | |||||||||
|
|||||||||